Clinical Pharmacogenomic MT-RNR1 Screening for Aminoglycoside-Induced Ototoxicity and the Post-Test Counseling...

Area of Science:

• Pharmacogenomics
• Genetics
• Otolaryngology

Background:

• Aminoglycoside antibiotics can cause ototoxicity and irreversible hearing loss.
• The m.1555A>G variant in the MT-RNR1 gene is a known risk factor for this hearing loss.
• Pre-emptive screening for this variant reduces pediatric ototoxicity.

Purpose of the Study:

• To highlight the need for professional guidelines for post-test pharmacogenomic counseling.
• To address challenges in communicating MT-RNR1 genetic testing results.
• To discuss familial care and heteroplasmy communication in pharmacogenomic counseling.

Main Methods:

• This is a perspective piece, not a primary research study.
• It synthesizes current knowledge on MT-RNR1 variant, aminoglycoside ototoxicity, and genetic counseling.
• It identifies key considerations for clinical implementation of genetic testing and counseling.

Main Results:

• Currently, no professional guidelines exist for pharmacogenomic counseling after MT-RNR1 testing.
• Effective communication strategies are crucial for patients and families.
• Longitudinal familial care and understanding heteroplasmy are important considerations.

Conclusions:

• Professional guidelines are urgently needed to support pharmacogenomic counseling for the m.1555A>G variant.
• Addressing familial implications and heteroplasmy is essential for comprehensive patient care.
• Implementing standardized counseling will improve outcomes and reduce ototoxicity risk.